DK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Delek US Holdings Inc (DK) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the stock has shown recent price momentum and positive technical indicators, the company's financial performance is weak, insider selling is significant, and analysts present mixed to bearish views. Additionally, there are no strong proprietary trading signals or congress trading data to support an immediate buy decision.
The technical indicators for DK are moderately positive. The MACD is above 0 and expanding positively, suggesting bullish momentum. The RSI is neutral at 65.403, and the moving averages (SMA_5 > SMA_20 > SMA_200) indicate a bullish trend. However, the stock is near resistance levels (R1: 46.196, R2: 47.707), which may limit further upside in the short term.
Recent price momentum with a 4.55% regular market gain.
Analysts from Raymond James and Mizuho raised price targets to $54, citing elevated refining margins and medium-term upside potential.
Rising oil prices and refining crack spreads have boosted profitability.
Significant insider selling, with a 176.11% increase in selling activity over the last month.
Mixed to bearish analyst ratings, with firms like BofA and Morgan Stanley maintaining underperform or neutral ratings.
Weak financial performance in Q4 2025, with net income and EPS dropping significantly YoY.
No recent congress trading data or proprietary trading signals to support a buy decision.
In Q4 2025, revenue increased by 2.35% YoY to $2.43 billion, but net income dropped by -118.92% YoY to $78.3 million. EPS also fell by -119.88% YoY to 1.3, and gross margin decreased significantly to 9.12, down -253.54% YoY. These metrics indicate weak financial health and profitability.
Analyst ratings are mixed, with some firms like Raymond James and Mizuho raising price targets to $54 and maintaining outperform ratings, citing medium-term upside due to elevated refining margins. However, other firms like BofA, Morgan Stanley, and Citi have underperform or neutral ratings, with price targets ranging from $33 to $40, reflecting a cautious outlook.
